regardless of the use of warfarin or aspirin. 1 Patients presenting with a lesion that is 70%
appear to be most vulnerable with a 1-year risk of 23% for a subsequent ipsilateral event. 2 …

We read with great interest the recent article published by Fiorella et al who report a
multicenter experience with the use of the Wingspan stent system (Boston Scientific) for the …

Intracranial atherosclerotic disease (ICAD) is a major cause of stroke and yet there are no
proven effective treatments for it. Medical therapy has been associated with a high rate of …

Background Randomized clinical trials have failed to prove that the safety and efficacy of
endovascular treatment for symptomatic intracranial atherosclerotic disease (ICAD) is better …

The consensus conference on intracranial atherosclerosis provides a comprehensive review
of the existing literature relevant to the epidemiology, diagnosis, prevention, and treatment of …

Background Stenting of symptomatic intracranial atherosclerosis remains under
investigation, yet this option to potentially avert subsequent stroke has been offered at select …

Large vessel intracranial atherosclerosis is increasingly recognized as a major cause of
ischemic stroke. In ethnically mixed populations, it may account for 8% of incident ischemic …

Chimowitz Treatment of Intracranial Atherosclerosis 2665 patients, as shown in analyses
that Seemant Chaturvedi and Tanya Turan led. These analyses suggested that patients with …

Intracranial atherosclerosis is a major cause of ischemic stroke. Depending on the
population studied, it accounts for 10 to 29% of brain ischemic events. 1 There is now no …

There is significant controversy which currently surrounds the management of patients with
symptomatic intracranial atherosclerotic disease (ICAD). A few salient topics within this …